Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT02117453

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02117453
  • EudraCT 2013-002531-15
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02117453. Randomized; quadruple masking; primary purpose prevention. Start 2014-10-27 (actual); primary completion 2019-11-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
Acronym
STATVAS
Condition
ANCA-associated Primary Necrotizing Vasculitides
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Placebo
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
URC-CIC Paris Descartes Necker Cochin (class: other)

Record details

Record id
cardio:ct-nct02117453
Content hash
a5b9675fa8ac9569fc6b08a4fb27edd9a80b5069ebdb173ed7be8b5664230c6c